Description
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Cancer-programmed cell death–C49H62N10O16S3—-[1]Maher KA et al. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100.|[2]Ziessman HA. Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues. J Nucl Med Technol. 2019 Sep;47(3):210-212.|[3]Can Wang, et al. Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats. Int J Biochem Cell Biol. 2020 Aug;125:105793.|[4]Can Wang, et al. Protective effect of cholecystokinin octapeptide on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. J Cell Biochem. 2020 Jul;121(7):3560-3569.–25126-32-3–1143.27–99.26–NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CNC2=C1C=CC=C2)NC(CNC([C@@H](NC([C@H](CC3=CC=C(C=C3)OS(=O)(O)=O)NC([C@H](CC(O)=O)N)=O)=O)CCSC)=O)=O)=O)CCSC)=O)CC(O)=O)=O)CC4=CC=CC=C4)=O–Cancer; Infection–DMF : 50 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)–Akt;Apoptosis;Cholecystokinin Receptor;PI3K—-Apoptosis;GPCR/G Protein;Neuronal Signaling;PI3K/Akt/mTOR–Peptides
